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N6-methyladenosine (m6A) in mRNA has emerged as a
crucial epitranscriptomic modification that controls
cellular differentiation and pluripotency. Recent
studies are pointing to a role for the RNA methylation
program in cancer self-renewal and cell fate, making
this a new and promising therapeutic avenue for
investigation.eIF4E-independent translation is activated in diverse dis-m6A, an epitranscriptomic mark that influences
cellular differentiation
One of the hallmark features of cancer is misregulated
gene expression. A newly recognized concept in the
regulation of gene expression is that mRNAs contain a
diverse set of modified nucleotides, and the location and
identity of these modifications within the transcriptome
constitute an ‘epitranscriptomic’ code. The initial con-
cept of the epitranscriptome was introduced as a result
of transcriptome-wide mapping of N6-methyladenosine
(m6A), which revealed that m6A is found in at least a
quarter of all mRNAs, typically near stop codons [1].
RNA methylation is mediated by a multiprotein ‘writer’
complex comprising RBM15–WTAP–METTL3–
METTL14 [2]. METTL3 is the sole methyltransferase re-
sponsible for forming m6A, whereas RBM15 couples the
methylation complex to mRNA to methylate adjacent
m6A residues [2]. WTAP acts as an adaptor, coupling
RBM15 to METTL3, whereas METTL14 positions RNA
substrates for methylation by METTL3. Notably, adeno-
sine methylation is reversible. Although FTO (fat mass
and obesity-associated protein) was reported to be an
m6A demethylase, it is now known that AlkB family
member 5 (ALKBH5) is the only enzyme to show physio-
logically relevant demethylation activity in vivo [3].* Correspondence: srj2003@med.cornell.edu; kharasm@mskcc.org
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(http://creativecommons.org/publicdomain/zeUnder normal conditions, the most prominent effect
of the presence of m6A is to induce mRNA degradation,
but, in response to certain types of cellular stress, the
m6A distribution across the transcriptome can change,
with the most notable effect being increases in the abun-
dance of m6A marks in the 5′-untranslated region of se-
lect mRNAs [4]. This methylation confers to the mRNA
the ability to be translated in a manner that does not re-
quire the canonical cap-binding protein eIF4E [4].
ease states, especially cancer.
A connection between m6A and cancer-relevant pro-
cesses is suggested from studies linking m6A to differen-
tiation pathways that control stem cell fate [5].
Pluripotent stem cells depleted of m6A show marked re-
sistance to stimuli that promote differentiation. These
cells retain pluripotency markers and fail to acquire gene
expression patterns seen in differentiated cells. By con-
trast, primed stem cells, which lack the ability to con-
tribute to blastocyst chimeras, are more prone to
differentiate and show enhanced and abnormal expres-
sion of differentiation markers upon depletion of m6A
[5]. These studies show that alterations in m6A levels
can alter differentiation pathways. As the pathways in-
volved in embryonic stem cell maintenance and differen-
tiation have been directly linked to the acquisition of
stem cell properties in both solid and hematological ma-
lignancies, m6A alterations might have a role in cancer
development (Fig. 1). Hypoxic environments and dysreg-
ulation of hypoxia-inducible factors (HIFs) have been
implicated in a variety of cancers, including brain, lung,
pancreatic, colon, ovarian, and many other cancers.ALKBH5 and m6A depletion as a driver of cancer
stem cell formation
In line with the above, recent studies point to a link be-
tween alterations in m6A levels and the abnormal cellu-
lar differentiation states present in cancer. In a variety of
tumors, cancer stem cell populations are readily detected
in hypoxic niches. Semenza and colleagues showed thatle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Cancer can be promoted by upregulating either N6-methyladenosine (m6A) demethylases or methyltransferase proteins. In breast cancer,
hypoxia increases the expression of ALKBH5 or ZNF217 through the activation of hypoxia-inducible factors (HIFs). ALKBH5 is an m6A demethylat-
ing enzyme, and ZNF217 inhibits the RNA methylation writer complex (RBM15–WTAP–METTL3–METTL14), resulting in a reduction of the levels of
the m6A modification in the mRNA of breast cancer pluripotency transcripts NANOG and KLF4, promoting their stability and increased expression.
This contributes to the reacquisition of the breast cancer stem cell phenotype in these cells. In myeloid leukemia, by contrast, increased levels of
components of the m6A methylation machinery proteins (RBM15–WTAP–METTL3–METTL14) are present, suggesting misregulated and increased
mRNA methylation. Thus, the increase in these proteins might alter the normal differentiation trajectory of hematopoietic stem cells, leading to
abnormal fates, including leukemic blasts. (Arrows indicate activation; ‘lightning bolts’ indicate misregulation of the RNA methylation program)
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stem cell formation and elevated levels of ALKBH5 in
breast cancer [6]. Notably, ALKBH5 was required for ac-
quisition of the breast cancer stem cell phenotype. The
authors observed that hypoxia increased the stability of
NANOG mRNA and its protein levels. This could reflect
ALKBH5-mediated NANOG mRNA demethylation or
an indirect effect of ALKBH5 expression on m6A levels
in NANOG mRNA [6]. NANOG is a key transcription
factor that is associated with pluripotency. In addition to
the effects of hypoxia on NANOG mRNA, hypoxia in-
duces the expression of the zinc-finger protein ZNF217,
which inhibits nuclear methylation [6]. Induction of
ZNF217 also reduces m6A levels in NANOG, as well as
in KLF4 [7]. The KLF4 transcription factor is a pluripo-
tency factor required for the maintenance of breast can-
cer stem cells. Thus, hypoxia reduces m6A levels to
promote the formation of breast cancer cells (Fig. 1).
m6A elevations in hematologic malignancies
While hypoxia decreases m6A levels, increases in the
abundance of m6A might also predispose to cancer. This
is supported by evidence that genes that encode proteins
that contribute to the RNA methylation complex areupregulated in myeloid leukemia (Fig. 1). Analysis of
The Cancer Genome Atlas (TCGA; https://cancergen-
ome.nih.gov/) shows that METTL3, METTL14, and
RBM15 are highly expressed in myeloid leukemia com-
pared with other cancers. These proteins appear to be
required for maintaining the abnormal differentiation
state seen in myeloid leukemia. A role for m6A in mye-
loid leukemias is supported by studies of WTAP deple-
tion. Bansal and colleagues found that WTAP expression
was elevated in cells derived from 32% of patients with
acute myeloid leukemia [8]. WTAP knockdown results
in reduced proliferation, increased differentiation, and
increased apoptosis in a leukemia cell line [8]. WTAP
knockdown is a highly efficient approach to deplete m6A
from mRNA. Thus, m6A depletion might account for
the anti-leukemia effects observed upon WTAP
depletion.
RBM15, another component of the m6A writer com-
plex, is also linked to myeloid leukemia. In this case,
RBM15 has a clear driver role in the development of
hematologic malignancy. Acute megakaryoblastic leuke-
mias were shown to be mediated by a chromosomal
translocation t(1;22) of RBM15 (also called OTT1) with
the MAL gene [9]. RBM15 has crucial roles in
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megakaryocyte leukemia cell line differentiation by con-
trolling the splicing of key differentiation genes, including
GATA1, RUNX1, TAL1, and c-MPL [10]. Because RBM15
directs m6A formation in the transcriptome [2], the onco-
genic effects of RBM15 overexpression and RBM15-MAL
translocation might reflect aberrant m6A formation.
Although each of the major proteins in the m6A methy-
lation complex—that is, RBM15, WTAP, METTL3, and
METTL14—show alterations in myeloid leukemias, de-
finitive demonstration of the role of m6A will require
mechanistic evidence linking m6A alterations to leukemia
phenotypes in these cancers.Conclusions
The modification m6A is an epitranscriptomic mark that
influences a wide variety of RNA processing steps, in-
cluding splicing, mRNA stability, and translation. Genes
associated with pluripotency and lineage-specific dif-
ferentiation are controlled by m6A levels, and reduced
m6A levels can lead to a misregulation of these genes
and the acquisition of stem cell characteristics. Alter-
natively, increases in m6A levels are expected to
stabilize these transcripts and would therefore be par-
ticularly problematic in tissues that are continuously
replenished from a stem cell population, such as the
hematopoietic lineage. Hematopoietic stem cells
traverse through distinct differentiation intermediates
in order to achieve their final differentiated state. Ele-
vations in m6A might alter the normal differentiation
pathway, resulting in cells being trapped in a progeni-
tor cell state.
Many unanswered questions remain. How conserved
are these pathways in other cancer types? Many cancer
subtypes are associated with abnormal differentiation
states or cancer stem cells, making it likely that inter-
ventions that influence m6A levels could therapeutically
alter the differentiation program. Will a systematic ana-
lysis of the marked transcripts in cancer reveal new tar-
gets for therapeutic intervention? Can pharmacologic
modulation of the RNA methylation program in various
cancers push cells toward differentiation? Another im-
portant question is whether targeting m6A would have
unwanted side-effects. As m6A might be used in every
cell for the regulation of gene expression, targeting m6A
might not provide a suitable therapeutic index. Finally,
the high reliance of myeloid leukemia cells on methyla-
tion complex proteins raises the hope that these cells
will show higher sensitivity to m6A pathway inhibitors
than other cell types.Abbreviations
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